Biomarkers in Transplant Recipients

Protocol Description

Transplant immunosuppression is associated with rejection, infection, malignancies and a variety of metabolic and organ-specific side effects. This protocol seeks to develop novel biomarkers that can be used to predict and diagnose these adverse events, or response to therapy. Biomarkers will be developed using a variety of techniques, including but not limited to: cell analysis, gene expression and sequence analysis, analysis of proteins and antibodies. Researchers will work from a variety of specimens, such as blood samples and residual tissue specimens obtained during biopsy and/or surgery.

Eligibility Criteria

The protocol is open to all types of transplant recipients at any time after transplantation or at any time before transplantation, once the recipient has been listed for transplantation.
Males: All ages
Females: All ages


Biological samples, such as blood, saliva, urine and stool, will be collected as part of normal clinical care for transplant. No separate procedures are required. Biopsies may be required in the case of liver or intestine transplants. If a biopsy is required as a part of standard clinical care, an extra piece of this biopsy may be collected for research purposes.
Visits: None beyond normal clinical care
Duration: Not applicable

Status: Open for Enrollment

Source(s) of Support

Pediatric Transplantation Department, Children’s Hospital of Pittsburgh of UPMC

Primary Investigator

Rakesh Sindhi, MD

Contact Information

For more information, please contact:
Katie Hindes Kalata, BS, MPH
Kym Smith, BS